VIVUS (VVUS) Sees Pressure Following Equity Offering
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
After falling nearly 11% intra-day, VIVUS (Nasdaq: VVUS) is continuing lower after-hours after announcing a 8.5 million equity offering. Shares last traded at $20.91, down another 1.6%.
Despite the recent selling pressure shares of VIVUS are up 95 percent since an FDA panel backed the company's obesity drug Qnexa.
Despite the recent selling pressure shares of VIVUS are up 95 percent since an FDA panel backed the company's obesity drug Qnexa.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- These 2 companies are best positioned to scale in U.S. AV market
- Walmart expected to beat Q2 estimates as tariff refunds lift margins
- UBS flags this name, sees "significant potential for stock outperformance"
Create E-mail Alert Related Categories
Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
